Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

New and experimental HIV treatments news

Show

From To
Once-daily raltegravir works as well as twice-daily for initial HIV treatment

A new formulation of the integrase inhibitor raltegravir (Isentress) taken once daily suppressed HIV viral load as well as the older formulation taken twice a day in people

Published
26 July 2016
By
Liz Highleyman
Dolutegravir plus lamivudine dual therapy works well as initial HIV treatment

A two-drug regimen of dolutegravir and the well-tolerated NRTI lamivudine led to sustained viral suppression for most people starting antiretroviral therapy (ART) for the first time in a

Published
25 July 2016
By
Liz Highleyman
Long-acting injectable drugs work well for HIV maintenance therapy

Two long-acting injectable antiretrovirals – cabotegravir and rilpivirine – administered once every 4 or 8 weeks maintained viral suppression in people who switched regimens with undetectable viral load,

Published
22 July 2016
By
Liz Highleyman
HIV will only be cured with combinations too, conference delegates hear

Curing people of HIV infection will have to involve combinations of drugs and approaches, just as HIV treatment does, delegates heard at the Towards a Cure workshop

Published
20 July 2016
By
Gus Cairns
Treatment Action Group: Pipeline Report 2016

Drugs, Diagnostics, Vaccines, Preventive Technologies, Research Toward a Cure, and Immune-Based and Gene Therapies in Development.

Published
15 July 2016
From
Treatment Action Group
New integrase inhibitor bictegravir looks promising in early studies

Gilead Sciences' novel integrase inhibitor bictegravir (formerly GS-9883) demonstrated favourable pharmacokinetics, good tolerability, an improved resistance profile compared to older drugs in its class, and potent antiviral activity

Published
06 July 2016
By
Liz Highleyman
The HIV Treatment Pipeline

“Depending on when you test positive for HIV, you could be looking at up to eight decades of treatment,” says Tim Horn of Treatment Action Group. “We need drugs that are gentler, kinder, better and cheaper.”

Published
28 June 2016
From
Poz
PRO 140 antibody injections maintain viral suppression in phase 2 study

Subcutaneous injections of PRO 140, a monoclonal antibody that blocks HIV entry into cells, was well tolerated and maintained undetectable viral load for more than a year after

Published
28 June 2016
By
Liz Highleyman
Gilead’s single tablet regimen Odefsey receives European marketing approval for HIV treatment

The European Commission has granted marketing authorization for Gilead Sciences' once-daily single tablet regimen (STR) Odefsey (emtricitabine 200 mg/rilpivirine 25 mg/tenofovir alafenamide 25 mg or R/F/TAF) for the treatment of HIV-1 infection in certain patients.

Published
27 June 2016
From
PharmaBiz
Investigational Integrase Inhibitor Bictegravir Safe and Effective Against HIV in Early Study

A new integrase inhibitor known as bictegravir (BIC, GS-9883) was found to be well tolerated and effective as HIV treatment in a 10-day monotherapy study, warranting further investigation of the drug, according to research presented at ASM Microbe 2016 in Boston, Massachusetts.

Published
21 June 2016
From
The Body
← First12345...91Next →

Filter by country

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close